INSIGHTS ON DRUG DEVELOPMENT
-
Advancing Cell Culture Strategies To Accelerate Biologics Development
Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks in transitioning from discovery to manufacturing.
-
Characterizing Quality Attributes Of GLP-1 Analogs By Light Scattering
Explore how light scattering reveals the structural integrity, aggregation, and stability of GLP-1 analogs to advance drug formulation and enhance treatment efficacy for type 2 diabetes and obesity.
-
Liberate Your Workflow: Flexible, Multi-Technique Chemical Data Analysis
Scientific workflows are no longer confined to one device. Cross-platform access to analytical data is becoming essential, helping researchers stay productive and collaborate more effectively.
-
Grace Capabilities Update February 2026: AI Drug Development
Discover support for your next small molecule drug substance program and learn how artificial intelligence and machine learning tools can be applied to accelerate API development.
-
Combining Patient Centricity And Commercial Viability In Pediatric Product Development8/15/2024
Medication acceptance and adherence are critical concerns in pediatric populations due to these patients’ rapid anatomical and physiological development.
-
Faster Clones, Simpler Process: What's Changing In CHO Expression?6/3/2026
This presentation examines how enhanced glutamine synthetase selection stringency, combined with a high-strength gene promoter, provides greater control over gene expression and supports CHO cell line development.
-
Navigating Challenges During Formulation Development9/11/2024
Gain valuable knowledge on addressing formulation stability, improving product shelf life, and enhancing overall product performance in biopharmaceutical studies.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Advanced Therapies Going Mainstream: Are We There Yet?11/14/2025
Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.
DRUG DEVELOPMENT SOLUTIONS
-
Ergonomic system microscope Leica DM1000 LED
The Leica DM1000 LED features long-life LED illumination that provides near daylight, bright illumination with constant color temperature and emits less heat.
The LED also eliminates the need for lamp changes, which saves time and money. Because of its low power consumption, the system is energy efficient. Users of the Leica DM1000 LED benefit from the system’s ability to uniquely adapt to every user.
It is ideal for all clinical laboratory applications, especially for cytology, haematology, and pathology. For special diagnostics requirements, the microscope is certified for in-vitro-diagnostics (IVD) like in-vitro-fertilization (IVF).
-
Research Use Only (RUO) lipid nanoparticle (LNP) reagents to deliver RNA into hematopoietic stem cells (HSCs) for cell and gene therapy applications.
-
Standalone instrument with touchscreen and built-in sample ports for small volumes and cuvettes
The SpectraMax® QuickDrop™ Micro-Volume Spectrophotometer quantifies very small amounts of DNA, RNA, oligos, and proteins.
-
The Powder Rheology Accessory expands the DHR’s capabilities to powders, enabling the characterization of behaviors during storage, dispensing, processing, and end-use.
-
Leica EZ
The Leica EZ4 educational stereomicroscope with 4.4:1 zoom for entry level university and college courses such as biology, anatomy and chemistry provides over 20 years of bright LED illumination which saves time and cost of replacement bulbs.